{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:20:27Z","timestamp":1791058827253,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1016\/j.autrev.2006.11.001","type":"journal-article","created":{"date-parts":[[2006,12,2]],"date-time":"2006-12-02T14:24:38Z","timestamp":1165069478000},"page":"190-195","source":"Crossref","is-referenced-by-count":65,"title":["Mycophenolate mofetil: What is its place in the treatment of autoimmune rheumatic diseases?"],"prefix":"10.1016","volume":"6","author":[{"given":"Luca","family":"Iaccarino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariaelisa","family":"Rampudda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagrazia","family":"Canova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Della Libera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piercarlo","family":"Sarzi-Puttinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Doria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1016\/j.autrev.2006.11.001_bib1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1191\/0961203305LU2109OA","article-title":"Mechanism of action of mycophenolate mofetil","volume":"14","author":"Allison","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2006.11.001_bib2","first-page":"1047","article-title":"Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients","volume":"32","author":"Pisoni","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2006.11.001_bib3","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.amjmed.2005.11.034","article-title":"Long-term prognosis and causes of death in systemic lupus erythematosus","volume":"119","author":"Doria","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2006.11.001_bib4","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.autrev.2005.10.001","article-title":"Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-study","volume":"5","author":"Manger","year":"2006","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2006.11.001_bib5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1191\/0961203304lu513oa","article-title":"Mycophenolate mofetil combined with prednisone for diffuse proliferative lupus nephritis: a histopathological study","volume":"13","author":"Ding","year":"2004","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2006.11.001_bib6","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM200010193431604","article-title":"Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group","volume":"343","author":"Chan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2006.11.001_bib7","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1440-1797.2005.00444.x","article-title":"Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis","volume":"10","author":"Ong","year":"2005","journal-title":"Nephrology"},{"key":"10.1016\/j.autrev.2006.11.001_bib8","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa043731","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis","volume":"353","author":"Ginzler","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2006.11.001_bib9","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1056\/NEJMoa031855","article-title":"Sequential therapies for proliferative lupus nephritis","volume":"350","author":"Contreras","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2006.11.001_bib10","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1681\/ASN.2004080686","article-title":"Long term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis","volume":"16","author":"Chan","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2006.11.001_bib11","doi-asserted-by":"crossref","unstructured":"Doria A, Iaccarino L, Arienti S, Rampudda M, Canova M, Rondinone R, et al. Mycophenolate mofetil and systemic lupus erythematosus. Lupus 2006; in press.","DOI":"10.1177\/0961203306071671"},{"key":"10.1016\/j.autrev.2006.11.001_bib12","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1191\/0961203305lu2163cr","article-title":"Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus","volume":"14","author":"Mak","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2006.11.001_bib13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.autrev.2004.09.005","article-title":"1st International Conference on Cutaneous Lupus Erythematosus. D\u00fcssendolf, Germany, September 1\u20135, 2004","volume":"4","author":"Kuhn","year":"2005","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2006.11.001_bib14","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.autrev.2005.01.003","article-title":"Clinical manifestation of cutaneous lupus erythematosus","volume":"4","author":"Werth","year":"2005","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2006.11.001_bib15","first-page":"393","article-title":"Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: poor results with mycophenolate mofetil","volume":"23","author":"Pisoni","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2006.11.001_bib16","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/08916930500285790","article-title":"Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus","volume":"38","author":"Briani","year":"2005","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2006.11.001_bib17","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1191\/0961203306lu2294rr","article-title":"Mycophenolate mofetil: what role in the treatment of lupus?","volume":"15","author":"Dooley","year":"2006","journal-title":"Lupus"},{"issue":"suppl 8","key":"10.1016\/j.autrev.2006.11.001_bib18","first-page":"S117","article-title":"Therapy of rheumatoid arthritis with mycophenolate mofetil","volume":"11","author":"Goldblum","year":"1993","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2006.11.001_bib19","first-page":"545","article-title":"Preliminary results in the therapy of psoriatic arthritis with mycophenolate mofetil","volume":"61","author":"Schr\u00e4der","year":"2002","journal-title":"Z Rheumatol"},{"key":"10.1016\/j.autrev.2006.11.001_bib20","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1067\/mjd.2000.104890","article-title":"Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil","volume":"42","author":"Grundmann-Kollmann","year":"2000","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 1","key":"10.1016\/j.autrev.2006.11.001_bib21","doi-asserted-by":"crossref","first-page":"s58","DOI":"10.1177\/096120330501400113","article-title":"Mycophenolate mofetil and skin diseases","volume":"14","author":"Hartmann","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2006.11.001_bib22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/08916930600622132","article-title":"Update on idiopathic inflammatory myopathies","volume":"39","author":"Briani","year":"2006","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2006.11.001_bib23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/08916930400022681","article-title":"Anti-Mi-2 antibodies","volume":"38","author":"Ghirardello","year":"2005","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2006.11.001_bib24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/08916930400022640","article-title":"Anti-Jo-1 antibodies","volume":"38","author":"Zampieri","year":"2005","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2006.11.001_bib25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/archderm.142.1.65","article-title":"Mycophenolate mofetil as an effective corticosteroid sparing therapy for recalcitrant dermatomyositis","volume":"142","author":"Edge","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2006.11.001_bib26","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/rheumatology\/keh499","article-title":"Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy","volume":"44","author":"Majithia","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2006.11.001_bib27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1159\/000051674","article-title":"Mycophenolate mofetil for dermatomyositis","volume":"202","author":"Tausche","year":"2001","journal-title":"Dermatology"},{"key":"10.1016\/j.autrev.2006.11.001_bib28","first-page":"1542","article-title":"Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis. A series of 4 cases","volume":"27","author":"Gelber","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2006.11.001_bib29","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/mus.10026","article-title":"Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome","volume":"25","author":"Schneider","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2006.11.001_bib30","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0022-510X(01)00478-6","article-title":"Mycophenolate (CellCept) treatment of myastenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis","volume":"185","author":"Mowzoon","year":"2001","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.autrev.2006.11.001_bib31","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/WNL.56.1.94","article-title":"Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases","volume":"56","author":"Chaudhry","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2006.11.001_bib32","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1212\/01.wnl.0000208416.32471.c0","article-title":"Mycophenolate mofetil in dermatomyositis. Is it safe?","volume":"66","author":"Rowin","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2006.11.001_bib33","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.autrev.2005.09.003","article-title":"Targeted therapy for systemic sclerosis","volume":"5","author":"Steen","year":"2006","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2006.11.001_bib34","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1191\/0961203305lu2170oa","article-title":"Modulation of intra-pulmonary TGF-\u03b2 expression by mycophenolate mofetil in lupus prone MRL\/lpr mice","volume":"14","author":"Guo","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2006.11.001_bib35","doi-asserted-by":"crossref","unstructured":"Nihtyanova SI, Brough GM, Black CM, Denton CP. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis -a retrospective analysis. Rheumatology 2006; in press.","DOI":"10.1093\/rheumatology\/kel244"},{"key":"10.1016\/j.autrev.2006.11.001_bib36","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jaut.2004.11.001","article-title":"Analysis of autoantibodies repertoires in small- and medium-sized vessels vasculitidies. Evidence for specific perturbations in polyartheritis nodosa, microscopic polyangiitis, Churg\u2013Strauss syndrome and Wegener's granulomatosis","volume":"24","author":"Chanseaud","year":"2005","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2006.11.001_bib37","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1681\/ASN.V1091965","article-title":"Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement","volume":"10","author":"Nowack","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2006.11.001_bib38","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/art.20240","article-title":"Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis","volume":"51","author":"Langford","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2006.11.001_bib39","doi-asserted-by":"crossref","first-page":"c100","DOI":"10.1159\/000089667","article-title":"Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis","volume":"102","author":"Koukoulaki","year":"2006","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.autrev.2006.11.001_bib40","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1191\/0961203306lu2307xx","article-title":"Quality of life comparison between corticosteroid-and-mycophenolate mofetil and corticosteroid-and-oral cyclophosphamide in the treatment of severe lupus nephritis","volume":"15","author":"Tse","year":"2006","journal-title":"Lupus"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997206002114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997206002114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T11:07:42Z","timestamp":1628161662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997206002114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S1568997206002114"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2006.11.001","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}